Trinity Biotech PLC (TRIB) — 6-K Filings

6-K Filings (50)

• 6-K Filing — May 6, 2026
• TRINITY BIOTECH Files Routine 6-K Report on March 25, 2026 — Mar 25, 2026
  TRINITY BIOTECH PLC filed a 6-K on March 25, 2026, indicating a routine report for foreign issuers. This filing, with accession number 0001178913-26-001700, inc
• Trinity Biotech PLC Files 6-K for Q2 2025 — Dec 23, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on December 23, 2025, reporting for the period ending June 30, 2025. The filing indicates the company is a foreign private
• 6-K Filing — Dec 18, 2025
• 6-K Filing — Nov 21, 2025
• 6-K Filing — Nov 18, 2025
• Trinity Biotech PLC Files 6-K, Incorporates S-8 Filings — Oct 23, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on October 23, 2025, to incorporate by reference into its existing S-8 registration statements. This filing follows the com
• Trinity Biotech Shareholders Approve All AGM Resolutions — Sep 30, 2025 Risk: low
  Trinity Biotech plc held its Annual General Meeting on September 30, 2025, where shareholders approved all proposed resolutions with at least 93% of votes cast.
• Trinity Biotech Files 2024 Annual Report and AGM Notice — Sep 8, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on September 8, 2025, to furnish its 2024 Annual Report as Exhibit 99.1. The filing also includes a "Letter from the Compan
• Trinity Biotech Regains Nasdaq Compliance — Sep 2, 2025 Risk: low
  On September 2, 2025, Trinity Biotech PLC announced it had regained compliance with the Nasdaq Stock Market's minimum bid price requirement. The company's ordin
• Trinity Biotech Gets Approval for Outsourced HIV Test Manufacturing — Aug 20, 2025 Risk: medium
  On August 20, 2025, Trinity Biotech PLC announced it received regulatory approval to begin offshore and outsourced manufacturing of its flagship rapid HIV Test.
• Trinity Biotech Gets FDA Clearance for Preeclampsia Test — Aug 15, 2025 Risk: low
  Trinity Biotech PLC announced on August 14, 2025, that it received FDA clearance for its PreClara™ preeclampsia testing service. This regulatory approval allows
• Trinity Biotech Files Routine 6-K Report — Aug 12, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on August 12, 2025, reporting for the month of August 2025. The company, based in Dublin, Ireland, is a foreign private iss
• Trinity Biotech Launches FDA-Cleared Preeclampsia Test — Aug 8, 2025 Risk: low
  On August 7, 2025, Trinity Biotech PLC announced the launch of its FDA-cleared Preeclampsia Testing Service. This new service aims to provide crucial diagnostic
• Trinity Biotech Launches AI Platform for $260B Wearable Market — Jul 24, 2025 Risk: medium
  On July 24, 2025, Trinity Biotech PLC announced the launch of CGM+, an AI-native platform designed for the AI wearable market, estimated at $260 billion. This f
• Trinity Biotech Reaches Profitability Inflection Point — Jul 1, 2025 Risk: medium
  Trinity Biotech PLC announced on July 1, 2025, that it has reached a profitability inflection point, a significant achievement in its strategic turnaround. The
• Trinity Biotech HIV Test Gets WHO Manufacturing Approval — Jun 24, 2025 Risk: low
  On June 24, 2025, Trinity Biotech plc announced it received World Health Organization (WHO) approval for the offshore and outsourced upstream manufacturing of i
• Trinity Biotech Files 6-K Report — May 15, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on May 15, 2025, reporting as a foreign private issuer. The filing indicates the company will file its annual reports under
• Trinity Biotech Appoints Interim CFO — Apr 4, 2025 Risk: low
  Trinity Biotech plc announced on April 4, 2025, the appointment of Susan O'Connor as Interim Chief Financial Officer. O'Connor, who has been with the company si
• Trinity Biotech Files March 2025 6-K Report — Mar 14, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on March 14, 2025, to report its activities for the month of March 2025. The filing indicates that Trinity Biotech is a for
• Trinity Biotech Files March 2025 6-K Report — Mar 13, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on March 13, 2025, to report its activities for the month of March 2025. This filing is incorporated by reference into seve
• Trinity Biotech Files 6-K for February 2025 — Feb 28, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on February 28, 2025, reporting as a foreign private issuer for the month of February 2025. The company is incorporated in
• Trinity Biotech Files Routine 6-K Report — Feb 6, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on February 6, 2025, to report for the month of February 2025. The company, based in Dublin, Ireland, is a foreign private
• Trinity Biotech Files 6-K for 2025 Reporting — Feb 4, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on February 4, 2025, to report its status as a foreign private issuer. The filing confirms that the company will file its a
• Trinity Biotech Files Routine 6-K Report — Jan 29, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on January 29, 2025, to report information for the month of January 2025. The company, based in Ireland, is a foreign priva
• Trinity Biotech Files Routine 6-K Report — Jan 28, 2025 Risk: low
  Trinity Biotech plc filed a Form 6-K on January 28, 2025, reporting its status as a foreign private issuer. The company, incorporated in Ireland with its princi
• Trinity Biotech Files 6-K for December 2024 — Dec 27, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on December 27, 2024, for the month of December 2024. The filing indicates that the company is a foreign private issuer and
• Trinity Biotech Files Routine 6-K Report — Dec 26, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on December 26, 2024, reporting for the month of December 2024. The company, based in Dublin, Ireland, is a foreign private
• Trinity Biotech Files 6-K, Reports Under Form 20-F — Dec 18, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on December 18, 2024, reporting as a foreign private issuer. The filing indicates the company is submitting its annual repo
• Trinity Biotech Files Routine 6-K Report — Dec 17, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on December 17, 2024, for the month of December 2024. The company, based in Ireland, is a foreign private issuer and is req
• Trinity Biotech PLC Files 6-K Report — Nov 15, 2024 Risk: low
  Trinity Biotech PLC filed a Form 6-K on November 15, 2024, to report information as a foreign private issuer. The filing indicates the company is submitting its
• Trinity Biotech Regains Nasdaq Compliance — Nov 7, 2024 Risk: low
  Trinity Biotech PLC announced on November 7, 2024, that it has regained compliance with Nasdaq's listing requirements. This filing includes a press release deta
• Trinity Biotech Acquires Prostate Cancer Test Developer EpiCapture — Oct 25, 2024 Risk: medium
  On October 25, 2024, Trinity Biotech PLC announced its acquisition of EpiCapture Limited, a company focused on developing a non-invasive test for monitoring agg
• Trinity Biotech Announces Positive CGM Trial Results — Oct 7, 2024 Risk: medium
  On October 7, 2024, Trinity Biotech PLC announced positive pre-pivotal trial results for its next-generation continuous glucose monitor (CGM) technology. The co
• Trinity Biotech Files 6-K Report — Oct 2, 2024 Risk: low
  Trinity Biotech plc filed a 6-K report on October 2, 2024, for the period ending June 30, 2024. The filing is a report of a foreign private issuer and includes
• Trinity Biotech Files Routine 6-K Report — Sep 30, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on September 30, 2024, reporting for the month of September 2024. As a foreign private issuer, the company is providing an
• Trinity Biotech Acquires Metabolomics Diagnostics — Sep 25, 2024 Risk: medium
  On September 25, 2024, Trinity Biotech PLC announced its acquisition of Metabolomics Diagnostics. This strategic move aims to expand Trinity Biotech's presence
• Trinity Biotech Files Routine 6-K Report — Sep 23, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on September 23, 2024, to report its activities for the month of September 2024. The company, based in Ireland, is a foreig
• Trinity Biotech PLC Updates Glucose Biosensor Technology Development — Sep 19, 2024 Risk: low
  On September 19, 2024, Trinity Biotech PLC announced an update regarding the ongoing development of its glucose biosensor technology. This filing is a Form 6-K,
• Trinity Biotech Updates Continuous Glucose Monitor Tech — Sep 10, 2024 Risk: medium
  Trinity Biotech PLC announced on September 9, 2024, an update on the ongoing development of its continuous glucose monitor (CGM) technology. This filing, submit
• Trinity Biotech plc Furnishes 2023 Annual Report — Sep 5, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on September 5, 2024, to furnish its 2023 Annual Report as Exhibit 99.1. The report covers the company's performance and fi
• Trinity Biotech Appoints New Chief Commercial Officer — Sep 4, 2024 Risk: low
  Trinity Biotech PLC announced on September 3, 2024, the appointment of Adrian Donohue as its new Chief Commercial Officer. Donohue brings global life sciences l
• Trinity Biotech Files 6-K, Confirms 20-F Reporting — Aug 29, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on August 29, 2024, to report its status as a foreign private issuer. The filing confirms that the company will file its an
• Trinity Biotech Secures Major TrinScreen HIV Orders — Aug 27, 2024 Risk: low
  Trinity Biotech PLC announced on August 26, 2024, that it has received substantial additional orders for its TrinScreen HIV product. This Form 6-K filing incorp
• Trinity Biotech Files August 2024 6-K Report — Aug 21, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on August 21, 2024, to report its activities for the month of August 2024. This filing is a report of a foreign private iss
• Trinity Biotech PLC Files August 2024 6-K Report — Aug 20, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on August 20, 2024, to report its activities for the month of August 2024. The company, an Irish-based issuer of diagnostic
• Trinity Biotech Files 6-K for August Reporting — Aug 7, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on August 7, 2024, to report information as a foreign private issuer. The filing indicates the company is submitting its re
• Trinity Biotech Files July 2024 Report (6-K) — Jul 11, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on July 11, 2024, to report its activities for the month of July 2024. The company, incorporated in Ireland, is a foreign p
• Trinity Biotech Files Routine 6-K Report — May 28, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on May 28, 2024, reporting for the month of May 2024. The company, based in Ireland, is a foreign private issuer and is fil
• Trinity Biotech Files Routine 6-K Report — May 16, 2024 Risk: low
  Trinity Biotech plc filed a Form 6-K on May 16, 2024, to report its status as a foreign private issuer. The company, based in Dublin, Ireland, is involved in th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX